首页 | 本学科首页   官方微博 | 高级检索  
     

STAT-3与Enolase-1在乳腺癌组织中的表达及意义
引用本文:杨洁,吴明富,叶双梅,蒋学锋,马全富,阚淳一,杨丽兰,卢运萍,王世宣,马丁. STAT-3与Enolase-1在乳腺癌组织中的表达及意义[J]. 肿瘤防治研究, 2012, 39(12): 1451-1455. DOI: 10.3971/j.issn.1000-8578.2012.12.011
作者姓名:杨洁  吴明富  叶双梅  蒋学锋  马全富  阚淳一  杨丽兰  卢运萍  王世宣  马丁
作者单位:1. 华中科技大学同济医学院附属同济医院妇产科,武汉,430030
2. 深圳市南山医院妇产科
3. 华中科技大学同济医学院附属同济医院肿瘤生物医学中心
基金项目:教育部新教师基金资助项目(200804871056)
摘    要:目的 探讨乳腺癌组织中信号转导及转录活化因子3(STAT-3)和糖酵解酶烯醇化酶(Enolase-1)的表达与雌孕激素受体、淋巴结转移、临床分期、病理分级等的关系.方法 免疫组织化学SP法检测126例乳腺癌和26例乳腺良性病变组织中STAT-3与Enolase-1的表达情况,并分析他们与临床病理参数之间的关系.结果 乳腺癌组织中STAT-3和Enolase-1的阳性表达率分别为82.5%和77.8%,明显高于乳腺良性病变组织(11.5%和7.7%),差异均有统计学意义(x2=42.416,P<0.05;x2=57.211,P<0.05);在有淋巴结转移的乳腺癌组织中阳性表达率分别为85.7%和90.5%,高于无淋巴结转移组,差异均有统计学意义(x2=9.184,P<0.05;x2=11.014,P<0.05).相关分析表明STAT-3和Enolase-1的表达呈正相关.在雌激素受体阳性(ER+)和/或孕激素受体阳性(PR+)或表皮生长因子受体2阳性(HER 2+)乳腺癌组织中,有淋巴结转移组中STAT-3和Enolase-1的表达水平均明显高于无淋巴结转移组,差异均有统计学意义(P<0.05).结论 STAT-3与Enolase-1的表达与乳腺癌的发生发展及侵袭转移相关,且二者有协同作用(r=0.379,P<0.05).在ER+和(或)PR+或HER-2+乳腺癌组织中,STAT-3和Enolase-1的高表达与淋巴结转移相关.在高表达STAT-3的乳腺癌组织中Enolase-1表达也较高,其联合检测可作为判断乳腺癌恶性程度、评价预后及指导治疗的一项评估指标.

关 键 词:乳腺肿瘤  淋巴结转移  STAT-3  Enolase-1
收稿时间:2012-01-10;

Expression and Clinical Signifiance of STAT-3 and Enolase-1 in Breast Cancer
Yang Jie,Ye Shuangmei,Jiang Xuefeng,Ma Quanfu,Kan Chunyi,Yang Lilan,Lu Yunping,Wang Shixuan,Ma Ding,Wu Mingfu. Expression and Clinical Signifiance of STAT-3 and Enolase-1 in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(12): 1451-1455. DOI: 10.3971/j.issn.1000-8578.2012.12.011
Authors:Yang Jie  Ye Shuangmei  Jiang Xuefeng  Ma Quanfu  Kan Chunyi  Yang Lilan  Lu Yunping  Wang Shixuan  Ma Ding  Wu Mingfu
Affiliation:1.Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;2.Department of Gynecology and Obstetrics,Shenzhen Nanshan Hospital;3.Cancer Biology Research Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology
Abstract:Objective
To investigate the expression of STAT-3 and Enolase-1 in breast cancer and its relationship with Estrogen receptor status,Progesterone receptor status,lymph node metastasis,clinical stages and histological grading.MethodsThe expression of STAT-3 and Enolase-1 were examined by immunohistochemical streptavid-peroxidase(S-P)assay in 126 cases of breast cancer and 26 cases of benign breast disease.And the significance of its expression was analyzed with clinicopathologic parameters.ResultsThe expression rates of STAT-3(77.8%)and Enolase-1(82.5%)in breast cancer were significantly higher than that in benign breast disease(11.5% vs.7.7%)and the expression of two proteins were positively correlated(χ2=42.416,P<0.05;χ2=57.211,P<0.05).The expression of STAT-3 and Enolase-1 in breast cancer has no significant difference in age,tumor size,histologic grading and clinical stages.Epression of STAT-3(85.7%)and Enolase-1(90.5%)in breast cancer with metastasis is significantly higher than that without metastasis (χ2=9.184,P<0.05;χ2=11.014,P<0.05).There was a significant correlation between the high expression of STAT-3 and axillary lymphatic metastasis in comparisons between positive estrogen and/or progesterone receptor expression and Her-2 positive expression(P<0.05).And there was a significant correlation between the high expression of Enolase-1 and axillary lymphatic metastasis in comparisons with positive estrogen or positive progesterone receptor expression and Her-2 positive expression(P<0.05).ConclusionBoth STAT-3 and Enolase-1 may be involved in the tumorgenesis development and metastasis of breast cancer.The high expression of STAT-3 and Enolase-1 in estrogen receptor or/and progesterone receptor or Her-2 positive breast cancer was associated with a high possibility of lymph node metastasis.The detection of STAT-3 and Enolase-1 may be helpful in the diagnosis and prognosis of breast cancer.
Keywords:Breast cancer  Lymph node metastasis  STAT-3  Enolase-1
本文献已被 万方数据 等数据库收录!
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号